HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Respiratory mechanics in an infant with perinatal lethal hypophosphatasia treated with human recombinant enzyme replacement therapy.

Abstract
Hypophosphatasia is a rare autosomal recessive disorder caused by deficient activity of tissue nonspecific alkaline phosphatase (TNSALP) and characterized by defective bone mineralization. In the perinatal lethal form, respiratory complications due to rachitic deformities of the thoracic cage and associated hypoplastic lungs are present. ENB-0040 is a bone-targeted human recombinant TNSALP fusion protein that aims to restore skeletal mineralization. The goal of this study was to characterize pulmonary and thoracic cage mechanics in an infant with the perinatal lethal form of hypophosphatasia under enzyme replacement therapy. Pulmonary function testing was performed on a preterm, 8-week-old patient with hypophosphatasia who was mechanically ventilated since birth because of severe chest wall insufficiency. The measurements consisted of respiratory impulse oscillation measurements (resistance and reactance), ventilatory mechanics (compliance and resistance), and thoracoabdominal motion (TAM) analysis. At baseline, chest wall compliance was 50% of normal, and the TAM indicated predominantly abdominal displacement. After 12 weeks of treatment, a consistent decrease in ventilator requirements and improvement in lung function and chest wall mechanics were observed and correlated with thoracic cage radiologic findings. Measurable changes in chest wall dynamics and respiratory mechanics using noninvasive technology were useful for respiratory management and therapeutic guidance of ENB-0040 treatment in this patient.
AuthorsElena Rodriguez, Michael B Bober, Lauren Davey, Arlene Zamora, Annelise B Li Puma, Aaron Chidekel, Thomas H Shaffer
JournalPediatric pulmonology (Pediatr Pulmonol) Vol. 47 Issue 9 Pg. 917-22 (Sep 2012) ISSN: 1099-0496 [Electronic] United States
PMID22328548 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2012 Wiley Periodicals, Inc.
Chemical References
  • Immunoglobulin G
  • Recombinant Fusion Proteins
  • Alkaline Phosphatase
  • asfotase alfa
Topics
  • Airway Resistance
  • Alkaline Phosphatase (therapeutic use)
  • Enzyme Replacement Therapy
  • Humans
  • Hypophosphatasia (drug therapy)
  • Immunoglobulin G (therapeutic use)
  • Infant
  • Male
  • Recombinant Fusion Proteins (therapeutic use)
  • Respiratory Function Tests
  • Respiratory Mechanics (drug effects)
  • Thoracic Wall (drug effects, physiopathology)
  • Tidal Volume

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: